BDAZ

A hit on all points. I was angling toward the market impact and potential SP implications in the short term if the secondary endpoints are glowing in the face of stellar MACE outcomes. If I remember correctly, the question was surrounding if BETonMACE hits a triple, can providers write APL for the sencondary indications without further proof of clinical utility.

And as always, appreciate your scientific acumen and the hard work you put in this space!